For the past two years, the biotech sector saw a surge of venture funding and IPOs. Now, by contrast, the sector is cooling down along with a broader contraction in funding globally.
While there is still funding available for biotech companies, investors are proceeding with more caution. For biotech companies, researchers, scientists and business leaders, it is critical to reassess their strategies and make the appropriate adjustments in order to achieve their next value inflection.
In this webinar, Drs. Fran Brown, Tina Morris and Patrick Smith will participate in a panel discussion on:
• Understanding the evolving funding landscape
• Re-evaluating your drug development and regulatory strategy
• Making every dollar count with smart, quality decisions
• Determining what data and insights you need to prove your argument
